

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Food and Drug Administration****Workshop to Discuss Development of a Women's Health Information Sharing Network**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of meeting.

The Food and Drug Administration's (FDA's) Office of Women's Health is announcing the following meeting: "Workshop to Develop a Women's Health Information Sharing Network" to discuss opportunities for national organizations to share information about their women's health education activities. There will be two meetings. One will focus on Hispanic/Latina populations, and the other will focus on all other communities. Representatives of national community-based organizations are invited. A continental breakfast will be provided.

**Date and Time:** The meetings will be held on April 12 and 13, 2007, from 8:30 am to 11:30 am.

**Location:** The meetings will be held at AARP, 601 East St., NW., Washington, DC 20049.

**Contact:** Susana Perry, FDA Office of Women's Health (HF-8), Food and Drug Administration, 5600 Fishers Lane, rm. 16-65, Rockville, MD 20857, 301-827-0350, FAX: 301-827-9194, e-mail: [susana.perry@fda.hhs.gov](mailto:susana.perry@fda.hhs.gov).

**Registration:** There is no fee, but pre-registration is required for security purposes by AARP. Seating is limited to 20 participants for each meeting.

If you need special accommodations due to a disability, please contact Susana Perry at least 7 days in advance (by April 6, 2007).

Dated: March 23, 2007.

**Jeffrey Shuren,**

*Assistant Commissioner for Policy.*

[FR Doc. 07-1546 Filed 3-27-07; 8:50 am]

**BILLING CODE 4160-01-S**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Survey of Complementary and Alternative Medicine Use by United States Cancer Patients Comment Period**

**AGENCY:** National Cancer Institute (NCI), National Institutes of Health (NIH), Department of Health and Human Services (HHS).

**ACTION:** Request for public comment.

**SUMMARY:** In compliance with the provisions of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comments on proposed data collection projects, the National Institutes of Health (NIH), National Cancer Institute (NCI) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

**DATES:** The National Survey of Cancer CAM Researchers' Recommendations public comment period will run from May 1, 2007 to June 30, 2007.

**ADDRESSES:** Comments may be submitted electronically at <http://www.cancer.gov/cam>.

**Background:** *Title:* National Survey of Complementary and Alternative Medicine Use by United States Cancer Patients. *Type of Information Collection Request:* New. *Need and Use of Information Collection:* There have been many regional surveys conducted about the use of CAM by cancer patients, but only one national survey which was published in 1992. The NCI is seeking to determine whether it should make an investment in the gathering of current nationally representative data on cancer patients' use of CAM.

**Request for Comments:** Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (a) Whether nationally representative data should be obtained on CAM use by U.S. cancer patients; (b) the type of data about CAM use by U.S. cancer patients which should be considered high priority; (c) whether international data on CAM use by cancer patients should be collected; and (d) appropriate uses for any data on CAM use by cancer patients that is collected.

Dated: February 28, 2007.

**Shea Buckman,**

*NCI OCCAM Communications and Outreach Manager, National Institutes of Health.*

[FR Doc. E7-5832 Filed 3-28-07; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Heart, Lung, and Blood Institute, Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Heart, Lung and Blood Institute Special Emphasis Panel, Research Project in Drug Therapy.

**Date:** April 26, 2007.

**Time:** 10:30 a.m. to 12:30 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

**Contact Person::** Mark Roltsch, PhD, Scientific Review Administrator, Review Branch/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7192, Bethesda, MD 20892-7924, 301-435-0287, [roltschm@nhlbi.nih.gov](mailto:roltschm@nhlbi.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Disease Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: March 22, 2007.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 07-1548 Filed 3-28-07; 8:45 am]

**BILLING CODE 4140-01-M**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Heart, Lung, and Blood Institute; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.